Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Waldenström macroglobulinemia

Waldenström macroglobulinemia

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Waldenström macroglobulinemia

26 trials tracked for Waldenström macroglobulinemia.

26Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 22 Other / NA 4
  1. Phase 2 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Completed
  2. Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Completed
  3. Phase 2 A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia Completed
  4. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
  5. Phase 2 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed
  6. Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed
Show 20 more trials
  1. Phase 2 BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia Completed
  2. Phase 2 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed
  3. Phase 2 Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma Completed
  4. Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed
  5. Phase 2 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed
  6. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Completed
  7. Phase 2 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Completed
  8. Phase 2 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed
  9. Phase 2 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Completed
  10. Phase 2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed
  11. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed
  12. Phase 2 Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed
  13. Phase 2 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  14. Phase 2 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed
  15. Phase 2 Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed
  16. Phase 2 CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed
  17. N/A Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma Completed
  18. N/A Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders Completed
  19. N/A Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed
  20. N/A High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors Completed

Showing the 26 most-cited and recently-updated of 26 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Lumbar Fractures as a Rare First Sign of Waldenström Macroglobulinemia
Rheumatology Sys. Review
Lumbar Fractures as a Rare First Sign of Waldenström Macroglobulinemia Rare Bone Fractures Linked to Waldenström Macroglobulinemia Identified
A systematic review found only 12 published cases of Waldenström macroglobulinemia first appearing as lumbar vertebral fractures.
New data identifies rare cases of lumbar vertebral fractures in patients with Waldenström macroglobulinemia, helping doctors distinguish the…
Frontiers Oct 23, 2026
Sequential BTK inhibitor therapy maintains hematological and renal stability in Waldenström macroglobulinemia with renal dysfunction
Allergy & Immunology Meta-analysis
Sequential BTK inhibitor therapy maintains hematological and renal stability in Waldenström macroglobulinemia with renal dysfunction New treatment approach shows promise for rare blood cancer patients
This case report and systematic review describes a patient with Waldenström macroglobulinemia and light-chain proximal tubulopathy treated w…
A new treatment plan for a rare blood cancer helped a patient maintain stable kidney function and a steady blood response.
Frontiers Oct 15, 2026
Bendamustine and rituximab treatment for Waldenström macroglobulinemia with renal AL amyloidosis shows hematologic response
Nephrology Sys. Review
Bendamustine and rituximab treatment for Waldenström macroglobulinemia with renal AL amyloidosis shows hematologic response New treatment approach shows promise for rare blood cancer
This case report describes a 71-year-old woman with Waldenström macroglobulinemia and renal AL amyloidosis treated with bendamustine plus ri…
A new drug combination helped a patient with a rare blood cancer and kidney issues, but it requires very careful monitoring.
Frontiers Jun 17, 2026
RCD chemotherapy in Waldenström macroglobulinemia with AL amyloidosis led to rapid progression and death
Rheumatology Guideline
RCD chemotherapy in Waldenström macroglobulinemia with AL amyloidosis led to rapid progression and death Rare Blood Cancer Causes Fast Kidney Failure
This case report and literature review describes a 75-year-old female with Waldenström macroglobulinemia and AL lambda-type amyloid nephropa…
When a rare blood cancer attacks the kidneys, standard treatments often fail to stop the fast progression to organ failure.
Frontiers Apr 15, 2026